SLN vs LCTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LCTX Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin while SLN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SLN trades at N/M Forward P/E with -11905.9% operating margin (+197.2% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, SLN sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SLN | LCTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.2B | $207.4M | Larger Scale | SLN |
| Trailing P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | +197.2% | -61.0% | Higher Growth | SLN |
| Operating Margin (TTM) Profitability | -11905.9% | -280.3% | Higher Margin | LCTX |
| Net Profit Margin Profitability | 0.0% | 16.2% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | -35.6% | 4.3% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 100% ($4โ$20) | 0% ($1โ$2) | Stronger Trend | SLN |
| Beta / 30D Volatility Risk Regime | 1.77ฮฒ ยท 4% Vol | 1.39ฮฒ ยท 79% Vol | Lower Realized Risk | SLN |
| Unified Institutional Score Composite Signal | 45.6 / 100 (HOLD) | 54.9 / 100 (HOLD) | Higher Composite | LCTX |